Xarelto has been linked to:

  • Internal Bleeding
  • Stroke
  • Heart Attack
  • Death

If you took Xarelto, suffered one of the above events, and was hospitalized for treatment, then you may be entitled to compensation. Get your FREE Consultation to see if you qualify.

  • Our dedicated attorneys can help.
  • Decades of proven trial experience.
  • Millions recovered for medical device victims.
  • Contact us now for a free consultation.
Call Our Hotline Now Help Available 24/7

Secure Your Free Xarelto Consultation Today

(888) 478-9711

Xarelto is one of the world’s most popular new blood thinners, promising millions of aFib patients an effective alternative to traditional anticoagulants like warfarin. But the drug was released without an antidote, leaving doctors without any way to reverse uncontrollable – and potentially fatal – bleeding events. Thousands of patients have already filed Xarelto lawsuits, and the first trials are coming soon.

Xarelto Lawsuit Infographic

Share this infographic on your own site. Just copy and paste the code below:

Is Xarelto Safe?

Xarelto is a brand name prescription blood thinner manufactured by Bayer and marketed in the United States by the Janssen Pharmaceuticals Unit of Johnson & Johnson. Xarelto is different from other blood thinners because it belongs to a certain class of drugs called Xa inhibitors, meaning that it keeps blood from clotting by blocking the chemical responsible for that function, thrombin. The active ingredient in Xarelto is rivaroxaban.

In the first quarter of 2012, Xarelto prescriptions were written for 130,000 residents of the United States and in 2013 alone, Xarelto sales made Bayer $1.3 billion dollars. These sales are expected to rise in the coming years. In its World Preview, EvaluatePharma estimated that Xarelto will generate 3.7 billion U.S. dollars in sales by 2018, making it the 19th best-selling drug in the world if these estimates prove true. These predicted sales will also be a dramatic increase in the drugs initial revenue, which was $596 million in 2012.

Since its release onto the market in 2011, over 11 million prescriptions for the drug have been written across the country. Xarelto’s initial popularity among patients and doctors was due to the fact that each prescription was a uniform dose. Starting a patient on a Xarelto regimen does not require the customized treatment plans and specialized diets that other popular blood thinners, such as Warfarin, do. The drug’s manufacturers marketed the drug as more convenient because there is no required blood monitoring and testing with a Xarelto regimen.

Latest Xarelto News

Laurence P. Banville - Xarelto Product Lawyer
Since Xarelto was released on the market there have been millions of prescriptions written for the drug, but these prescriptions have come at a life-threatening price. Here you will find the latest news about Xarelto lawsuits and the effects the drug has had on people who took the drug not knowing its full side effects.

March 8, 2017- Xarelto Pushed By Drug Companies For Heart Attack Prevention Despite Lawsuits

Bayer Healthcare and Janssen Pharmaceuticals reported on February 8 that Phase 3 Compass clinical trials for Xarelto were stopped early because it showed great success. The trials were meant to determine if the drug could be used to prevent cardiac events in patients. The companies are currently faced with thousands of lawsuits regarding the severe bleeding side effects connected to Xarelto. Despite these suits, they indicated in a statement that they would be looking to obtain FDA approval for the anticoagulant to be promoted as a heart attack prevention drug.

February 7, 2017 – New Lawsuit Alleging Death From Drug Side Effects Joins Xarelto MDL

Another lawsuit regarding Xarelto has joined MDL 2592. The children of a deceased woman have filed suit alleging that the manufacturers failed to warn consumers, medical professionals, and the FDA of the serious, life-threatening side effects associated with the drug. In particular, these plaintiffs reference the negligence of the companies to release the anticoagulant without an antidote to reverse the effects of the drug in the case of emergency bleeding. The plaintiffs, in this case, allege that as a result of Xarelto, their mother suffered life-threatening bleeding, anemia, sepsis and kidney failure before she passed away in January of 2016. The first of the four bellwether trials for MDL 2592 is scheduled to begin in March of this year.

January 24, 2017 – Study Finds Xarelto To Be Least Favorable Among New Blood Thinners

A new study was published on December 31, 2016, in the medical journal Gastroenterology in which Mayo Clinic researchers compared the safety profiles of Xarelto, Eliquis, and Pradaxa. All of the anticoagulants looked at are fairly new and have been developed as replacements to the traditional warfarin. All three drugs have had reports of uncontrollable bleeding and complications as well as thousands of lawsuits claiming injury or wrongful death. Researchers found in the population-based study that Xarelto had higher bleeding rates than the other two anticoagulants studied and it was the least favorable. Drugmakers are still seeking a reversal agent for Xarelto which would make it much safer.

December 2, 2016 – Woman’s Suit Added To Xarelto Litigation

A woman filed a complaint on November 14 against numerous defendants, including Bayer AG, in Cook County Circuit Court. The plaintiff alleges that due to her use of the anticoagulant, Xarelto, she suffered severe physical injuries. Her complaint also alleges that the defendants who manufacture and distribute the drug were responsible for her injuries because they failed to warn consumers of the possible side effects of the drug. The plaintiff seeks compensation greater than $50,000.

November 7, 2016 – Bellwether Selection Process Determined For Philadelphia Xarelto Mass Tort Program

The Philadelphia mass tort program consists of about 1,000 pending Xarelto lawsuits which are similar to the over 7,000 Xarelto lawsuits consolidated in an MDL in the Eastern District of Louisiana. A judge recently ruled how bellwether cases will be selected for trial. Selection of bellwether trial cases will begin in the summer of 2017 and a total of 24 cases will be selected. Trials are scheduled to begin in September and December of 2017. Bellwether cases for the Louisiana MDL have already been selected and are scheduled to begin in early 2017.

October 6, 2016 – Higher Bleeding Risk Found With Xarelto When Compared To Pradaxa

According to study findings published in the journal JAMA Internal Medicine, Xarelto has a “slight increased risk of bleeding” in comparison to Pradaxa in patients with atrial fibrillation. For the study which was conducted at the FDA’s Center for Drug Evaluation and Research, data was collected on close to 119, 000 Medicare patients with atrial fibrillation treated with either Xarelto or Pradaxa. Little difference was found in stroke risk but a statistically significant increase of stomach and brain bleeding was found in patients taking Xarelto.

September 19, 2016 – Judge Fallon Extends Deadline To File Xarelto Lawsuits Another 90 Days

In mid-August, weeks after the bellwether cases were selected for trial in the MDL, a  deadline extension of 90 days was allowed for some plaintiffs to file Xarelto lawsuits. Judge Fallon explained that the extension was made due to the high influx of complaints seen by the clerk’s office. The first bellwether trial is scheduled to occur in February and there are currently over 7,000 lawsuits consolidated in the MDL. Meanwhile, in Philadelphia, the first trials in the mass tort program are expected to begin next year, in August, as a bellwether program is being negotiated.

August 19, 2016 – Trials For Xarelto Litigation Have Been Selected And Scheduled

Judge Eldon Fallon, who is overseeing the Xarelto MDL 2592, has indicated that four cases will be going to trial starting in February of next year. These four cases are part of the bellwether trials selected in order to streamline the litigation which is now comprised of over 6,400 lawsuits. The first trial will include plaintiffs who originally filed in Louisiana and suffered a bleeding event while between the ages of 50 to 90 years old. The second trial will have plaintiffs who suffered a brain bleed, a stroke, or an injury that resulted in death. The third trial will include plaintiffs who filed in Mississippi originally, suffered gastrointestinal bleeding, and were between the ages of 40 to 80 years old when the event occurred. The fourth trial will take place in Texas involving a bleeding event.   

April 14, 2016- Xarelto Litigation Plaintiffs Band Together To Jointly File A Lawsuit

A group of 10 Xarelto litigation plaintiffs from various states have banded together to jointly file a lawsuit. The reason they are doing this is due to the resemblances in their allegations towards the adverse results, mainly death, suffered from using Xarelto. Those filing this litigation are groups of family members who represent deceased loved ones, who died due to serious medical complications they had while using Xarelto. The lawsuits were jointly filed on November 20, 2015.

March 16, 2016- Xarelto Bellwether Cases Due To Be Chosen

A total of 40 cases are set to be chosen for the Xarelto bellwether pool, this is by order issued by U.S. District Judge Eldon Fallon. Selection of the cases will be made with each side choosing 10 cases and a further 20 cases that will be selected randomly. In December 2014, Xarelto lawsuits were combined into a multi-district litigation (MDL).

The Product Lawyers Logo

Free Xarelto Case Evaluation

  • This field is for validation purposes and should be left unchanged.
Contact The Product Lawyers for a free consultation (888) 478-9711

Contact The Product Lawyers for a free consultation

(888) 478-9711